| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.727 | 0.007 | 0.727 | Streptokinase A inhibitor | 0.255 0.1 DBMET02452 | ||
| 0.675 | 0.005 | 0.675 | Amyloid beta aggregation inhibitor | |||
| 0.635 | 0.01 | 0.635 | 12-Lipoxygenase inhibitor | 0.223 0.127 DBMET02452 | ||
| 0.54 | 0.004 | 0.54 | Chelator | |||
| 0.492 | 0.004 | 0.492 | Heat shock protein 90 alpha antagonist | 0.18 0.063 DBMET02452 | ||
| 0.51 | 0.038 | 0.51 | 15-Lipoxygenase inhibitor | 0.277 0.145 DBMET02452 | ||
| 0.493 | 0.028 | 0.493 | GABA C receptor rho-3 antagonist | 0.305 0.112 DBMET02452 | ||
| 0.464 | 0.019 | 0.464 | Antiamyloidogenic | 0.157 0.138 DBMET02452 | ||
| 0.446 | 0.004 | 0.446 | Heat shock protein 90 antagonist | 0.145 0.08 DBMET02452 | ||
| 0.404 | 0.004 | 0.404 | Porphobilinogen synthase inhibitor | 0.156 0.019 DBMET02452 | ||
| 0.445 | 0.051 | 0.54 | Antiobesity | 0.54 0.029 DBMET02452 | DBMET02452 | |
| 0.392 | 0.023 | 0.392 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | |||
| 0.387 | 0.029 | 0.387 | Calcium channel activator | 0.286 0.106 DBMET02452 | ||
| 0.381 | 0.042 | 0.381 | Lipoxygenase inhibitor | |||
| 0.404 | 0.076 | 0.404 | 5 Hydroxytryptamine release inhibitor | |||
| 0.336 | 0.031 | 0.336 | Peroxidase inhibitor | |||
| 0.354 | 0.049 | 0.354 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.15 0.143 DBMET02452 | ||
| 0.364 | 0.071 | 0.364 | Thioredoxin glutathione reductase inhibitor | |||
| 0.335 | 0.043 | 0.335 | Free radical scavenger | |||
| 0.398 | 0.11 | 0.398 | Transcription factor inhibitor | |||
| 0.291 | 0.01 | 0.291 | Cystathionine beta-synthase inhibitor | 0.113 0.064 DBMET02452 | ||
| 0.285 | 0.007 | 0.285 | Mannose-6-phosphate isomerase inhibitor | 0.182 0.041 DBMET02452 | ||
| 0.327 | 0.075 | 0.327 | Cholesterol antagonist | 0.288 0.099 DBMET02452 | ||
| 0.28 | 0.033 | 0.28 | Non-steroidal antiinflammatory agent | 0.219 0.058 DBMET02452 | ||
| 0.254 | 0.007 | 0.254 | Phosphodiesterase 4D inhibitor | |||
| 0.348 | 0.103 | 0.348 | Antibacterial | 0.328 0.116 DBMET02452 | ||
| 0.253 | 0.021 | 0.253 | Succinate dehydrogenase inhibitor | 0.168 0.083 DBMET02452 | ||
| 0.283 | 0.054 | 0.283 | 5 Hydroxytryptamine uptake stimulant | 0.193 0.166 DBMET02452 | ||
| 0.345 | 0.121 | 0.345 | Calcium channel L-type activator | |||
| 0.256 | 0.04 | 0.256 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | |||
| 0.268 | 0.056 | 0.268 | Pyruvate kinase inhibitor | |||
| 0.253 | 0.048 | 0.253 | RNA-directed DNA polymerase inhibitor | 0.246 0.052 DBMET02452 | ||
| 0.3 | 0.102 | 0.3 | Prostaglandin dehydrogenase inhibitor | |||
| 0.218 | 0.021 | 0.218 | Glutamate receptor antagonist | 0.176 0.035 DBMET02452 | ||
| 0.209 | 0.025 | 0.209 | Arachidonic acid antagonist | 0.147 0.092 DBMET02452 | ||
| 0.236 | 0.053 | 0.236 | DNA methyltransferase I inhibitor | |||
| 0.238 | 0.06 | 0.238 | MAP kinase kinase 2 inhibitor | |||
| 0.257 | 0.08 | 0.257 | Aldehyde oxidase inhibitor | |||
| 0.181 | 0.004 | 0.181 | Botulinum neurotoxin type A inhibitor | 0.083 0.015 DBMET02452 | ||
| 0.173 | 0.006 | 0.173 | Phosphodiesterase XI inhibitor | 0.145 0.012 DBMET02452 | ||
| 0.173 | 0.006 | 0.173 | Phosphodiesterase 11A inhibitor | 0.145 0.012 DBMET02452 | ||
| 0.24 | 0.078 | 0.24 | Tyrosine 3 hydroxylase inhibitor | |||
| 0.256 | 0.095 | 0.256 | Hypoxia-inducible factor 1 alpha inhibitor | |||
| 0.194 | 0.035 | 0.206 | Alkaline phosphatase inhibitor | 0.206 0.031 DBMET02452 | DBMET02452 | |
| 0.177 | 0.02 | 0.177 | Potassium channel (Ca-activated) activator | |||
| 0.239 | 0.083 | 0.239 | Aryl hydrocarbon receptor agonist | |||
| 0.16 | 0.007 | 0.16 | Sphingosine 1-phosphate receptor 4 agonist | 0.093 0.028 DBMET02452 | ||
| 0.24 | 0.089 | 0.24 | Antioxidant | 0.182 0.13 DBMET02452 | ||
| 0.154 | 0.004 | 0.154 | Catechol O-methyltransferase inhibitor | |||
| 0.184 | 0.038 | 0.184 | M18 aspartyl aminopeptidase inhibitor | |||
| 0.159 | 0.013 | 0.159 | MAP kinase kinase 1 inhibitor | |||
| 0.148 | 0.005 | 0.148 | Heat shock protein 90 beta antagonist | |||
| 0.161 | 0.02 | 0.161 | Creatine kinase inhibitor | |||
| 0.177 | 0.039 | 0.177 | Topoisomerase II inhibitor | |||
| 0.149 | 0.012 | 0.149 | Phenylalanine 4-hydroxylase inhibitor | |||
| 0.146 | 0.011 | 0.146 | Glutamate release inhibitor | 0.095 0.051 DBMET02452 | ||
| 0.192 | 0.06 | 0.192 | Mcl-1 antagonist | |||
| 0.312 | 0.181 | 0.312 | Caspase 9 stimulant | |||
| 0.173 | 0.045 | 0.173 | Phosphodiesterase inhibitor | |||
| 0.157 | 0.029 | 0.157 | Ca2+-transporting ATPase inhibitor | |||
| 0.202 | 0.074 | 0.202 | Neurotrophic factor enhancer | |||
| 0.153 | 0.028 | 0.153 | UDP-glucose 4-epimerase inhibitor | |||
| 0.161 | 0.036 | 0.207 | Pregnane X receptor agonist | 0.207 0.009 DBMET02452 | DBMET02452 | |
| 0.147 | 0.025 | 0.147 | Hedgehog signaling inhibitor | |||
| 0.2 | 0.079 | 0.2 | DNA methylase inhibitor | |||
| 0.203 | 0.083 | 0.203 | Nitric-oxide synthase stimulant | |||
| 0.137 | 0.019 | 0.137 | Macrophage migration inhibitory factor inhibitor | |||
| 0.174 | 0.056 | 0.174 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | |||
| 0.162 | 0.045 | 0.162 | MAP kinase kinase inhibitor | |||
| 0.17 | 0.057 | 0.17 | Interferon gamma antagonist | |||
| 0.182 | 0.071 | 0.25 | Dual specificity phosphatase 3 inhibitor | 0.25 0.04 DBMET02452 | DBMET02452 | |
| 0.214 | 0.103 | 0.219 | Superoxide dismutase inhibitor | 0.219 0.098 DBMET02452 | DBMET02452 | |
| 0.131 | 0.023 | 0.131 | NADH dehydrogenase inhibitor | |||
| 0.144 | 0.039 | 0.144 | 5 Hydroxytryptamine 3A agonist | |||
| 0.17 | 0.066 | 0.17 | Catenin beta inhibitor | |||
| 0.179 | 0.074 | 0.179 | LIM domain kinase 1 inhibitor | |||
| 0.144 | 0.039 | 0.144 | Sphingosine 1-phosphate receptor 4 antagonist | |||
| 0.138 | 0.036 | 0.138 | Carbonic anhydrase XV inhibitor | 0.098 0.07 DBMET02452 | ||
| 0.122 | 0.021 | 0.122 | Cannabinoid receptor antagonist | 0.078 0.042 DBMET02452 | ||
| 0.142 | 0.041 | 0.142 | Ferrochelatase inhibitor | |||
| 0.164 | 0.066 | 0.164 | Cyclin-dependent kinase 8 inhibitor | |||
| 0.133 | 0.035 | 0.133 | Beta glucuronidase inhibitor | |||
| 0.145 | 0.048 | 0.145 | Sphingosine 1-phosphate receptor 2 antagonist | |||
| 0.106 | 0.01 | 0.106 | Dihydroorotate dehydrogenase inhibitor | 0.065 0.024 DBMET02452 | ||
| 0.125 | 0.031 | 0.125 | Alcohol dehydrogenase inhibitor | |||
| 0.108 | 0.014 | 0.108 | Cannabinoid CB1 receptor antagonist | 0.078 0.028 DBMET02452 | ||
| 0.148 | 0.056 | 0.148 | NADPH oxidase inhibitor | |||
| 0.157 | 0.065 | 0.157 | GABA C receptor rho-2 antagonist | |||
| 0.105 | 0.014 | 0.105 | Cannabinoid CB2 receptor antagonist | |||
| 0.104 | 0.014 | 0.104 | GABA B receptor agonist | |||
| 0.167 | 0.078 | 0.229 | Dual specificity phosphatase inhibitor | 0.229 0.043 DBMET02452 | DBMET02452 | |
| 0.096 | 0.008 | 0.096 | Corticotropin releasing factor 2 receptor antagonist | 0.071 0.026 DBMET02452 | ||
| 0.089 | 0.003 | 0.089 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.049 0.016 DBMET02452 | ||
| 0.179 | 0.095 | 0.179 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | |||
| 0.163 | 0.081 | 0.163 | ATPase inhibitor | |||
| 0.093 | 0.013 | 0.093 | Phosphodiesterase II inhibitor | 0.056 0.038 DBMET02452 | ||
| 0.116 | 0.037 | 0.116 | Estrogen receptor beta antagonist | |||
| 0.083 | 0.005 | 0.083 | Pregnane X receptor antagonist | 0.058 0.037 DBMET02452 | ||
| 0.129 | 0.051 | 0.129 | Interleukin 8 antagonist | |||
| 0.101 | 0.024 | 0.115 | HIV-1 integrase inhibitor | 0.115 0.017 DBMET02452 | DBMET02452 | |
| 0.124 | 0.048 | 0.124 | Estrogen antagonist | |||
| 0.12 | 0.045 | 0.12 | DOPA decarboxylase inhibitor | |||
| 0.133 | 0.06 | 0.133 | CC chemokine 6 receptor antagonist | |||
| 0.208 | 0.136 | 0.208 | Gastrin inhibitor | |||
| 0.083 | 0.014 | 0.083 | Transcription factor RelA inhibitor | 0.068 0.033 DBMET02452 | ||
| 0.156 | 0.088 | 0.156 | Antipruritic | |||
| 0.144 | 0.075 | 0.144 | Neuropeptide Y1 antagonist | |||
| 0.073 | 0.005 | 0.073 | Acid-sensing ion channel blocker | 0.056 0.012 DBMET02452 | ||
| 0.081 | 0.013 | 0.081 | Phosphodiesterase 2A inhibitor | 0.046 0.04 DBMET02452 | ||
| 0.113 | 0.046 | 0.113 | Pim-1 kinase inhibitor | |||
| 0.088 | 0.021 | 0.088 | Purinergic P2X1 antagonist | |||
| 0.109 | 0.043 | 0.109 | Lanosterol 14 alpha demethylase inhibitor | |||
| 0.175 | 0.11 | 0.175 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | |||
| 0.093 | 0.028 | 0.123 | HIV-1 integrase (3'-Processing) inhibitor | 0.123 0.018 DBMET02452 | DBMET02452 | |
| 0.147 | 0.082 | 0.147 | Hexokinase inhibitor | |||
| 0.116 | 0.052 | 0.116 | 5-Lipoxygenase inhibitor | |||
| 0.067 | 0.004 | 0.067 | Corticotropin releasing factor 1 receptor antagonist | 0.06 0.004 DBMET02452 | ||
| 0.096 | 0.034 | 0.096 | D-Ala-D-Ala ligase inhibitor | |||
| 0.074 | 0.015 | 0.074 | NMDA receptor subunit 3B antagonist | |||
| 0.139 | 0.08 | 0.139 | Heat shock protein 70 antagonist | |||
| 0.087 | 0.029 | 0.087 | Transforming growth factor antagonist | |||
| 0.098 | 0.039 | 0.098 | NAD(P)H dehydrogenase (quinone) inhibitor | |||
| 0.23 | 0.171 | 0.23 | Histamine release inhibitor | |||
| 0.071 | 0.014 | 0.071 | NMDA receptor subunit 3A antagonist | |||
| 0.205 | 0.149 | 0.205 | Insulysin inhibitor | |||
| 0.061 | 0.004 | 0.061 | Bradykinin B2 receptor antagonist | 0.055 0.005 DBMET02452 | ||
| 0.153 | 0.097 | 0.153 | Tumour necrosis factor antagonist | |||
| 0.119 | 0.066 | 0.134 | Cholesterol synthesis inhibitor | 0.134 0.054 DBMET02452 | DBMET02452 | |
| 0.089 | 0.036 | 0.089 | Estrogen receptor alpha antagonist | |||
| 0.158 | 0.105 | 0.158 | Anesthetic general | |||
| 0.082 | 0.03 | 0.114 | HIV-1 integrase (Strand Transfer) inhibitor | 0.114 0.018 DBMET02452 | DBMET02452 | |
| 0.103 | 0.051 | 0.103 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | |||
| 0.136 | 0.088 | 0.136 | Sphingosine 1-phosphate receptor 5 antagonist | |||
| 0.188 | 0.142 | 0.188 | Neuropeptide Y2 antagonist | |||
| 0.076 | 0.03 | 0.076 | Aryl hydrocarbon receptor antagonist | |||
| 0.077 | 0.031 | 0.077 | NMDA receptor glycine site agonist | |||
| 0.166 | 0.121 | 0.166 | Dyrk kinase inhibitor | |||
| 0.148 | 0.103 | 0.148 | Amyloid beta precursor protein antagonist | |||
| 0.099 | 0.055 | 0.099 | HIV-1 integrase (Overall Integration) inhibitor | |||
| 0.075 | 0.031 | 0.075 | Glutamate (mGluR6) antagonist | |||
| 0.11 | 0.066 | 0.11 | Activin receptor-like kinase 4 inhibitor | |||
| 0.081 | 0.037 | 0.081 | Cyclin B3 inhibitor | |||
| 0.088 | 0.045 | 0.097 | Glycine receptor antagonist | 0.097 0.035 DBMET02452 | DBMET02452 | |
| 0.12 | 0.078 | 0.12 | Alpha-N-acetylglucosaminidase inhibitor | |||
| 0.253 | 0.211 | 0.253 | Apoptosis agonist | |||
| 0.085 | 0.044 | 0.085 | CYP2A6 inhibitor | |||
| 0.186 | 0.147 | 0.186 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.052 | 0.014 | 0.052 | Bradykinin antagonist | 0.044 0.018 DBMET02452 | ||
| 0.051 | 0.015 | 0.051 | Glutamate (mGluR group II) antagonist | |||
| 0.092 | 0.057 | 0.092 | Potassium channel activator | |||
| 0.126 | 0.091 | 0.206 | Cell wall synthesis inhibitor | 0.206 0.028 DBMET02452 | DBMET02452 | |
| 0.142 | 0.108 | 0.142 | TRKC antagonist | |||
| 0.08 | 0.047 | 0.08 | GABA aminotransferase inhibitor | |||
| 0.077 | 0.045 | 0.077 | Histidine decarboxylase inhibitor | |||
| 0.081 | 0.048 | 0.081 | Glutamate (mGluR) antagonist | |||
| 0.277 | 0.245 | 0.277 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | |||
| 0.115 | 0.084 | 0.115 | Amylase inhibitor | |||
| 0.084 | 0.053 | 0.084 | Transforming growth factor beta 3 antagonist | |||
| 0.065 | 0.035 | 0.071 | Androgen agonist | 0.071 0.029 DBMET02452 | DBMET02452 | |
| 0.062 | 0.034 | 0.062 | Alcohol oxidase inhibitor | |||
| 0.098 | 0.069 | 0.098 | GABA C receptor agonist | |||
| 0.044 | 0.016 | 0.044 | CF transmembrane conductance regulator antagonist | |||
| 0.096 | 0.068 | 0.096 | Anabolic | 0.087 0.084 DBMET02452 | ||
| 0.075 | 0.048 | 0.075 | Nav1.8 sodium channel blocker | 0.065 0.063 DBMET02452 | ||
| 0.102 | 0.075 | 0.102 | GABA C receptor antagonist | |||
| 0.161 | 0.134 | 0.161 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.035 | 0.009 | 0.035 | Thyroid hormone agonist | 0.03 0.012 DBMET02452 | ||
| 0.051 | 0.025 | 0.051 | Benzodiazepine antagonist | 0.046 0.036 DBMET02452 | ||
| 0.084 | 0.06 | 0.084 | NMDA receptor antagonist | 0.077 0.07 DBMET02452 | ||
| 0.078 | 0.054 | 0.078 | Topoisomerase II alpha inhibitor | |||
| 0.114 | 0.091 | 0.127 | Sodium channel (voltage-gated) blocker | 0.127 0.077 DBMET02452 | DBMET02452 | |
| 0.173 | 0.149 | 0.173 | 5 Hydroxytryptamine release stimulant | |||
| 0.037 | 0.014 | 0.037 | Estrogen-related receptor beta antagonist | |||
| 0.192 | 0.169 | 0.192 | Thyroid hormone antagonist | |||
| 0.035 | 0.014 | 0.035 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.112 | 0.091 | 0.112 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.035 | 0.014 | 0.035 | Glutamate (mGluR2) antagonist | |||
| 0.063 | 0.043 | 0.063 | NMDA receptor agonist | 0.063 0.043 DBMET02452 | ||
| 0.084 | 0.065 | 0.084 | Granulocyte macrophage colony stimulating factor agonist | |||
| 0.031 | 0.012 | 0.031 | NMDA receptor glycine site antagonist | |||
| 0.072 | 0.054 | 0.072 | S-adenosyl-L-methionine decarboxylase inhibitor | |||
| 0.023 | 0.005 | 0.023 | CC chemokine 9 receptor antagonist | 0.02 0.007 DBMET02452 | ||
| 0.047 | 0.028 | 0.047 | Dihydroorotase inhibitor | |||
| 0.055 | 0.036 | 0.055 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.129 | 0.111 | 0.129 | MAP kinase 3 inhibitor | |||
| 0.082 | 0.064 | 0.082 | Histamine N-methyltransferase inhibitor | |||
| 0.14 | 0.123 | 0.14 | Ca2+/calmodulin-dependent protein kinase inhibitor | |||
| 0.193 | 0.176 | 0.193 | Transcription factor NF kappa B inhibitor | |||
| 0.052 | 0.035 | 0.052 | Aconitate hydratase inhibitor | |||
| 0.05 | 0.033 | 0.05 | Topoisomerase II beta inhibitor | |||
| 0.036 | 0.02 | 0.036 | Glutamate (mGluR4) agonist | |||
| 0.027 | 0.011 | 0.027 | Aggrecanase 2 inhibitor | |||
| 0.047 | 0.032 | 0.047 | Thymidylate synthase inhibitor | |||
| 0.034 | 0.019 | 0.034 | ATP citrate lysase inhibitor | |||
| 0.051 | 0.036 | 0.168 | Factor IXa inhibitor | 0.168 0.004 DBMET02452 | DBMET02452 | |
| 0.079 | 0.066 | 0.079 | Androgen antagonist | |||
| 0.13 | 0.118 | 0.13 | CF transmembrane conductance regulator agonist | |||
| 0.04 | 0.028 | 0.04 | Dopamine D5 agonist | |||
| 0.038 | 0.026 | 0.038 | Glutamate (mGluR8) agonist | |||
| 0.028 | 0.017 | 0.028 | Hedgehog signaling activator | |||
| 0.081 | 0.07 | 0.081 | Interleukin 5 antagonist | |||
| 0.042 | 0.031 | 0.042 | Glutamate (mGluR group III) agonist | |||
| 0.028 | 0.017 | 0.044 | Kynurenine 3 monooxygenase inhibitor | 0.044 0.008 DBMET02452 | DBMET02452 | |
| 0.015 | 0.004 | 0.015 | Corticotropin releasing factor antagonist | 0.01 0.005 DBMET02452 | ||
| 0.182 | 0.172 | 0.182 | Thyroid hormone beta antagonist | |||
| 0.031 | 0.022 | 0.031 | Potassium channel small-conductance Ca-activated activator | |||
| 0.048 | 0.039 | 0.061 | Potassium channel (Inward rectifier) activator | 0.061 0.018 DBMET02452 | DBMET02452 | |
| 0.027 | 0.018 | 0.027 | Sodium/glucose cotransporter 2 inhibitor | |||
| 0.046 | 0.038 | 0.058 | Potassium channel (ATP-sensitive) activator | 0.058 0.018 DBMET02452 | DBMET02452 | |
| 0.099 | 0.091 | 0.099 | Beta amyloid protein antagonist | |||
| 0.046 | 0.039 | 0.046 | Dopamine beta hydroxylase inhibitor | |||
| 0.123 | 0.117 | 0.13 | Adenylate cyclase stimulant | 0.13 0.102 DBMET02452 | DBMET02452 | |
| 0.05 | 0.043 | 0.05 | Maillard reaction inhibitor | |||
| 0.062 | 0.056 | 0.062 | Potassium channel large-conductance Ca-activated activator | |||
| 0.105 | 0.099 | 0.105 | Glycogen synthase kinase-3 alpha inhibitor | |||
| 0.058 | 0.053 | 0.058 | CDC25B inhibitor | |||
| 0.043 | 0.038 | 0.043 | Glutamate (mGluR5) antagonist | |||
| 0.032 | 0.028 | 0.032 | Phosphoglycerate kinase inhibitor | |||
| 0.106 | 0.103 | 0.109 | Sodium channel blocker | 0.109 0.099 DBMET02452 | DBMET02452 | |
| 0.015 | 0.012 | 0.015 | Dipeptidyl peptidase IX inhibitor | |||
| 0.024 | 0.021 | 0.024 | CXC chemokine 2 receptor antagonist | |||
| 0.053 | 0.051 | 0.053 | Leukotriene C antagonist | |||
| 0.09 | 0.088 | 0.09 | Adenylate kinase inhibitor | |||
| 0.056 | 0.054 | 0.056 | 5 Hydroxytryptamine 5A antagonist | |||
| 0.036 | 0.034 | 0.036 | Vanilloid 3 antagonist | |||
| 0.084 | 0.083 | 0.084 | Xanthine oxidase inhibitor | |||
| 0.098 | 0.097 | 0.098 | Interleukin 2 antagonist | |||
| 0.06 | 0.059 | 0.066 | HIV-1 reverse transcriptase inhibitor | 0.066 0.052 DBMET02452 | DBMET02452 | |
| 0.045 | 0.046 | 0.116 | H+/K+-transporting ATPase inhibitor | 0.116 0.007 DBMET02452 | DBMET02452 | |
| 0.057 | 0.062 | 0.064 | Neuraminidase (influenza) inhibitor | 0.064 0.044 DBMET02452 | DBMET02452 | |
| 0.038 | 0.047 | 0.044 | Dihydrofolate reductase inhibitor | 0.044 0.029 DBMET02452 | DBMET02452 | |
| 0.022 | 0.035 | 0.027 | Complement factor 1s inhibitor | 0.027 0.012 DBMET02452 | DBMET02452 | |
| 0.073 | 0.093 | 0.103 | Triose-phosphate isomerase inhibitor | 0.103 0.045 DBMET02452 | DBMET02452 | |
| 0.035 | 0.057 | 0.042 | Glutamate (mGluR5) agonist | 0.042 0.039 DBMET02452 | DBMET02452 | |
| 0.01 | 0.037 | 0.021 | Sodium/hydrogen exchanger inhibitor | 0.021 0.008 DBMET02452 | DBMET02452 | |
| 0.072 | 0.104 | 0.129 | DNA directed RNA polymerase inhibitor | 0.129 0.032 DBMET02452 | DBMET02452 | |
| 0.017 | 0.054 | 0.025 | Vanilloid 2 agonist | 0.025 0.019 DBMET02452 | DBMET02452 | |
| 0.029 | 0.067 | 0.04 | Thymidine kinase inhibitor | 0.04 0.03 DBMET02452 | DBMET02452 | |
| 0.02 | 0.07 | 0.027 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.027 0.018 DBMET02452 | DBMET02452 | |
| 0.052 | 0.104 | 0.078 | CDC25A inhibitor | 0.078 0.045 DBMET02452 | DBMET02452 | |
| 0.021 | 0.073 | 0.059 | Estrogen agonist | 0.059 0.03 DBMET02452 | DBMET02452 | |
| 0.065 | 0.119 | 0.172 | Gastric antisecretory | 0.172 0.018 DBMET02452 | DBMET02452 | |
| 0.102 | 0.164 | 0.253 | Hemostatic | 0.253 0.022 DBMET02452 | DBMET02452 | |
| 0.035 | 0.103 | 0.055 | Heparanase inhibitor | 0.055 0.033 DBMET02452 | DBMET02452 | |
| 0.073 | 0.143 | 0.128 | Cyclooxygenase 1 inhibitor | 0.128 0.072 DBMET02452 | DBMET02452 | |
| 0.035 | 0.106 | 0.073 | Carbonic anhydrase V inhibitor | 0.073 0.04 DBMET02452 | DBMET02452 | |
| 0.09 | 0.166 | 0.143 | Protein-tyrosine phosphatase inhibitor | 0.143 0.086 DBMET02452 | DBMET02452 | |
| 0.035 | 0.12 | 0.065 | Carbonic anhydrase VA inhibitor | 0.065 0.053 DBMET02452 | DBMET02452 | |
| 0.074 | 0.16 | 0.117 | TRPA1 agonist | 0.117 0.062 DBMET02452 | DBMET02452 | |
| 0.077 | 0.164 | 0.113 | Cyclooxygenase inhibitor | 0.113 0.108 DBMET02452 | DBMET02452 | |
| 0.036 | 0.127 | 0.093 | Carbonic anhydrase XIII inhibitor | 0.093 0.041 DBMET02452 | DBMET02452 | |
| 0.068 | 0.16 | 0.125 | Cyclooxygenase 2 inhibitor | 0.125 0.074 DBMET02452 | DBMET02452 | |
| 0.084 | 0.183 | 0.165 | Diuretic | 0.165 0.065 DBMET02452 | DBMET02452 | |
| 0.063 | 0.17 | 0.083 | CC chemokine 5 receptor agonist | 0.083 0.054 DBMET02452 | DBMET02452 | |
| 0.088 | 0.199 | 0.112 | Vanilloid 1 agonist | 0.112 0.11 DBMET02452 | DBMET02452 | |
| 0.026 | 0.153 | 0.059 | NMDA 2B receptor antagonist | 0.059 0.032 DBMET02452 | DBMET02452 | |
| 0.051 | 0.22 | 0.169 | Multidrug resistance-associated protein 1 inhibitor | 0.169 0.018 DBMET02452 | DBMET02452 | |
| 0.011 | 0.18 | 0.053 | Carbonic anhydrase inhibitor | 0.053 0.052 DBMET02452 | DBMET02452 | |
| 0.004 | 0.23 | 0.024 | Estrone sulfatase inhibitor | 0.024 0.014 DBMET02452 | DBMET02452 | |
| 0.156 | 0.405 | 0.441 | Antiinflammatory | 0.441 0.115 DBMET02452 | DBMET02452 | |
| 0.047 | 0.312 | 0.258 | Cell adhesion inhibitor | 0.258 0.014 DBMET02452 | DBMET02452 | |
| 0.034 | 0.301 | 0.298 | Cell adhesion molecule inhibitor | 0.298 0.005 DBMET02452 | DBMET02452 | |
| 0.004 | 0.412 | 0.167 | Cholecystokinin A agonist | 0.167 0.003 DBMET02452 | DBMET02452 | |
| 0.008 | 0.437 | 0.225 | Selectin antagonist | 0.225 0.009 DBMET02452 | DBMET02452 | |
| 0.004 | 0.465 | 0.18 | Cholecystokinin A antagonist | 0.18 0.005 DBMET02452 | DBMET02452 | |
| 0.035 | 0.499 | 0.186 | Platelet adhesion inhibitor | 0.186 0.079 DBMET02452 | DBMET02452 | |
| 0.003 | 0.471 | 0.258 | Cholecystokinin agonist | 0.258 0.003 DBMET02452 | DBMET02452 | |
| 0.004 | 0.485 | 0.048 | Factor XI inhibitor | 0.048 0.011 DBMET02452 | DBMET02452 | |
| 0.02 | 0.505 | 0.152 | Thrombolytic | 0.152 0.081 DBMET02452 | DBMET02452 | |
| 0.005 | 0.501 | 0.065 | Factor XIa inhibitor | 0.065 0.01 DBMET02452 | DBMET02452 | |
| 0.004 | 0.534 | 0.11 | Cholecystokinin antagonist | 0.11 0.007 DBMET02452 | DBMET02452 | |
| 0.004 | 0.577 | 0.037 | 1,3-Beta-glucan synthase inhibitor | 0.037 0.005 DBMET02452 | DBMET02452 | |
| 0.003 | 0.669 | 0.062 | Cholecystokinin B antagonist | 0.062 0.008 DBMET02452 | DBMET02452 | |
| 0.013 | 0.715 | 0.405 | Angiogenesis stimulant | 0.405 0.021 DBMET02452 | DBMET02452 | |
| 0.005 | 0.746 | 0.103 | Elastase inhibitor | 0.103 0.009 DBMET02452 | DBMET02452 | |
| 0.007 | 0.78 | 0.467 | Anticoagulant | 0.467 0.012 DBMET02452 | DBMET02452 | |
| 0.005 | 0.781 | 0.081 | Thrombin inhibitor | 0.081 0.04 DBMET02452 | DBMET02452 | |
| 0.007 | 0.828 | 0.28 | Cholecystokinin B agonist | 0.28 0.004 DBMET02452 | DBMET02452 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |